Becton Dickinson and Co (BDX)
合理估值基本面
60
价格
$178.61
市值
$50.07B
第一部分 · 这家公司值多少
概览
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Baxter sells infusion pumps, IV sets and injectable drug delivery systems to the same hospital pharmacies and purchasing groups that buy BD's medication delivery and infusion business.
After absorbing Hospira's infusion business, ICU Medical bids against BD for hospital contracts on infusion pumps, IV sets and vascular access consumables.
Abbott competes with BD's Life Sciences arm for hospital laboratory budgets, supplying diagnostic instruments and infectious-disease testing systems to the same clinical labs.
This family-owned German group competes with BD across the whole IV therapy line — catheters, infusion pumps, syringes and needles — in hospitals in Europe and the United States.
Teleflex competes head-on with BD's interventional and vascular access catalogue, above all central venous and PICC catheters bought by the same hospital departments.
Medtronic overlaps with BD on needles and syringes and on vascular and urology intervention devices sold to the same surgical and interventional specialists.
资产负债表与流动性
营收
$22.41B
最近12个月（截至2026/6/30）
净利润
$941M
最近12个月（截至2026/6/30）
自由现金流
$2.67B
股东权益合计
$25.39B
负债合计
$29.93B
流动比率
0.87
利息覆盖率
3.92
债务/EBITDA
3.33
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$216.42
当前价格
$178.61
安全边际
+17.5%
公允价值区间
$140.67 - $292.17
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
54.08
ROE
6.6%
市净率（P/B）
2.00
P/FCF
15.22
毛利率
46.7%
ROIC
4.4%
盈利能力雷达图
价值创造（经济护城河）
ROIC
4.4%
WACC
6.7%
ROIC − WACC
-2.3 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（17）
- EPS shows upward trend
- Gross Margin 46.7%
- P/FCF 15.22
- P/B Ratio 2.00
- Debt/Equity ratio
- Operating Margin 10.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 6.3%
- Analyst Consensus 57% Buy
- Earnings Quality (OCF/NI) 4.20
- Share Dilution -0.9%
- Piotroski F-Score 8/9
未通过（10）
- EPS CAGR 2.88%
- Price CAGR 3.43%
- ROIC 4.4%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
- Earnings Surprise avg 1.9%
- PEG Ratio 3.94
- Net Margin Trend 4.2% vs 8.0%
不可用（1）
- Dividend Payout NaN%
Piotroski F-评分
财务状况强健
盈利质量
高质量：盈利有现金流支撑
股权稀释
正在回购股份，对股东友好
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 52 |
| Dr. Michael D. Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | 55 |
| Mr. Michael C. Feld | Executive VP & Chief Revenue Officer | 44 |
| Mr. Vitor Roque | Executive VP & CFO | 42 |
| Ms. Elizabeth McCombs | Executive VP & CTO | 48 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | - |
| Ms. Denise Russell Fleming | Executive Vice President & Chief Information Officer | 54 |
| Mr. Shawn C. Bevec | Senior Vice President of Investor Relations | - |
| Ms. Lanesha T. Minnix J.D. | Executive VP & General Counsel | 50 |
| Carla Burigatto | Senior VP & Chief Communications Officer | - |
审计风险
3
董事会风险
6
薪酬风险
5
股东权利风险
1
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for BDX, sourced from Markets Gazette.